TIL Desk/Business/New Delhi/ Glenmark Pharmaceuticals and Torrent Pharmaceuticals Thursday said they have entered into a licensing agreement to co-market diabetes drug Remogliflozin Etabonate in India. “Under the terms of the agreement, Glenmark will receive an upfront payment, license fees and royalties for the non-exclusive sub-license rights from Torrent.
“Glenmark will manufacture and supply Remogliflozin while Torrent will market the drug under its own trademark ‘Zucator’ in India,” Glenmark Pharma said in a regulatory filing. The company, however, did not disclose financial details of the licensing agreement.
Glenmark Pharma said in April 2019 it had received approval from the Drugs Controller General of India (DCGI) for Remogliflozin Etabonate after successfully completing phase-3 clinical trials in which the drug demonstrated good efficacy and safety profile in a head-to-head comparison against Dapagliflozin.
Subsequently, Glenmark launched Remogliflozin, indicated in the treatment of Type 2 Diabetes Mellitus in adults under the brand names ‘Remo’ and ‘Remozen’.
